Global ADC Drug Overview: Can Photoimmunotherapy Highlight the Encirclement

In recent years, antibody-drug conjugates (ADCs) have been widely sought after due to their excellent clinical performance and market returns, and they have maintained a high degree of enthusiasm for research and development worldwide.

ADC drug basic structure

No.

The stage of ADC drugs in global progress

Since the first ADC product Mylotarg (gemtuzumab ozogamicin) was launched in 2000, a total of 11 ADC products have been approved for launch worldwide.

The global marketed and approved ADC drugs

No.

The global marketed and research ADC drugs involved in the treatment field situation

There are few competitors in the rest of the treatment field, but there is no shortage of heavy potential products.

In terms of target selection, it is similar to the drugs already on the market.

The status of ADC drug targets in global progress

No.

Near-infrared photoimmunotherapy (NIR-PIT) is a kind of molecular targeted phototherapy for cancer.

Traditional immunotherapy, such as immune-activating cytokine therapy, checkpoint inhibition, engineered Tcells, etc.

NIR-PIT-induced immunogenic cell death

After the antibody drug binds to the tumor surface antigen, under near-infrared light stimulation, IR700 undergoes a light-induced ligand release reaction, releasing hydrophilic side chains, resulting in a significant increase in the hydrophobicity of the remaining part.

IR700 chemical reaction principle and schematic diagram of coupling protein changes

Cetuximab sarotalocan is the first product of photoimmune ADC, which is formed by linking water-soluble silicon phthalocyanine derivative IRDye700DX and cetuximab.

Cetuximab sarotalocan principle of action

In addition to Cetuximab sarotalocan, there are a total of five immunological ADC projects under research worldwide, all of which are in the pre-clinical or drug discovery stage, and all use IR700 as their effector molecule.

The status of the research and development of immunological ADC products

At present, the broad market prospects of ADC drugs have set off an upsurge in research and development of related products on a global scale.

Reference

1.
Antibody-Drug Conjugates: The Last Decade.
Pharmaceuticals (Basel)

2.
Near-Infrared Photoimmunotherapy of Cancer.
Acc.
Chem.
Res.

3.
Regulatory approval of photoimmunotherapy: photodynamictherapy that induces immunogenic cell death.
Oncoimmunology